Autotelic Bio announced that it has entered into an exclusive license and technology transfer agreement with Aché Laboratórios Farmacêuticos S.A., Brazil’s leading pharmaceutical company, for ATB-101, the world’s first combination therapy designed to simultaneously treat hypertension and diabetes.

The signing ceremony was held on June 18, 2025, at the Korea Biohealth Hub (#1578), a joint promotional booth operated by the Korea Health Industry Development Institute (KHIDI), during the BIO International Convention (BIO USA) in Boston, United States.

Under the agreement, Aché has secured the exclusive rights to manufacture and commercialize ATB-101 in the Brazilian market. With over 50 years of history and more than 300 brands, Aché is one of Brazil’s leading pharmaceutical companies, boasting a strong distribution network and high brand recognition across Latin America.

Through this agreement, Autotelic Bio will receive technology transfer milestone payments as well as sales-based royalties. Given Brazil’s position as the largest pharmaceutical market in Latin America, the company expects to generate substantial royalty revenue from the partnership.

ATB-101 is an innovative combination therapy that enables the simultaneous management of hypertension and diabetes. Following the exclusive supply agreement signed with Mexico’s Chinoin in June 2024, Autotelic Bio successfully entered the Brazilian market within one year, further demonstrating the strong market competitiveness of ATB-101 and enhancing its potential for expansion across Latin America.

In addition, the company is accelerating its R&D efforts for entry into the U.S. market after being selected for the “2024 Strategic Technology International Joint R&D Program” led by the Ministry of Trade, Industry and Energy, securing KRW 3 billion in research funding.

ATB-101 is the world’s first combination therapy for hypertension and type 2 diabetes, formulated with olmesartan, an antihypertensive agent, and dapagliflozin, an oral antidiabetic drug. The product significantly improves medication adherence and convenience for patients managing both chronic conditions.

The drug has received Phase 3 IND approval from the Ministry of Food and Drug Safety (MFDS) and is currently undergoing Phase 3 clinical trials at approximately 32 major hospitals in Korea, including Seoul National University Bundang Hospital, involving patients with essential hypertension and type 2 diabetes.

Following the successful completion of its ongoing Phase 3 trial and confirmation of safety and efficacy, Autotelic Bio plans to pursue global commercialization. To support this strategy, the company has already secured composition patents in Korea, the United States, Japan, Russia, Mexico, and Brazil, and continues to expand its intellectual property portfolio to additional countries, including China.